Target intelligence / Profile preview

miR-29b binding site on progranulin mRNA (null)

Target
null
Molecular classification
Other (microRNA target site), Regulatory RNA element
01

Overview

The miR-29b binding site on progranulin mRNA (GRN mRNA) is an evolutionarily conserved sequence located in the 3′ untranslated region (3′UTR) of the GRN transcript. This site serves as a docking region for microRNA-29b (miR-29b), a small non-coding RNA that downregulates GRN by binding to this specific 3′UTR sequence, thereby repressing translation or destabilizing the transcript. Disruption of this interaction by targeted antisense oligonucleotides can relieve miR-29b-mediated silencing and increase progranulin protein production, offering a potential therapeutic approach for conditions associated with progranulin deficiency such as frontotemporal dementia. The site itself is not a protein or classic receptor but rather an RNA regulatory element that mediates a critical step in the post-transcriptional control of gene expression[1][3][4][5].

Other names
miR-29b site on GRN mRNAmicroRNA-29b binding site on progranulin mRNAmiR-29b regulatory site in GRN 3′UTR
02

Mechanism of action

Antisense oligonucleotides bind to the miR-29b binding site on GRN mRNA, preventing miR-29b from downregulating GRN and thus increasing progranulin protein translation[3][4][5] - This post-transcriptional interference relieves the suppression normally imposed by miR-29b on GRN mRNA[1]

03

Biological functions

Post-transcriptional regulation of gene expressionRegulation of progranulin (GRN) protein levelsControl of mRNA stabilityControl of translation
04

Disease associations

Neurodegenerative disease (notably, frontotemporal dementia associated with progranulin deficiency)[1][4][3][5]Potentially cancer and fibrosis (indirect through miR-29b roles)[2]
05

Safety considerations

Off-target effects of antisense oligonucleotidesUnintended upregulation of GRN in non-target tissuesRoles of miR-29b in fibrosis, apoptosis, and tumorigenesis may introduce complex systemic effects[2]Unknown long-term consequences on cellular processes normally regulated by miR-29b[2][4]
06

Interacting drugs

Antisense oligonucleotides targeting the miR-29b binding site (notably ASOs developed to increase progranulin by sterically blocking miR-29b interaction)[3][4][5]
07

Biomarkers

Progranulin (GRN) protein level in plasma, CSF, or tissue as a biomarker of efficacy and target engagement[1][4][5]miR-29b levels (for potential patient stratification and response)[1][2]

Beyond the preview

Go deeper on miR-29b binding site on progranulin mRNA (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-29b binding site on progranulin mRNA (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call